TABLE 3.
Main therapeutic characteristics of the 100 patients treated with continuous intravenous cefazolin
| Therapeutic characteristic | Value |
|---|---|
| Median (range) daily dose (g) | 6 (4-16) |
| Median (range) duration of treatment (days) | 42 (14-82) |
| Antibiotic combined with cefazolin (no. of patients) | |
| Gentamicin followed by rifampin | 59 |
| Rifampin | 29 |
| Other | 12 |
| Median (range) serum cefazolin concn (mg/liter) | |
| Days 2-10 | 63 (13-203) |
| Days 11-21 | 57 (29-128) |
| Median (range) serum cefazolin concn | |
| (mg/liter)/MIC90 (mg/liter)a | 60.75 (13-203) |
| No. of patients with dose adaptation | |
| Total | 47 |
| Increase | 9 |
| Decrease | 38 |
| No. of patients receiving outpatient parenteral | |
| antibiotic therapy | 51 |
| No. of patients with AEs | 2 |
a
MIC90 for cefazolin-susceptible staphylococcal strains, 1 mg/liter (16).